You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

284 Results
Document
Oct 2018
Document
Jan 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    venetoclax - Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) according to clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
venetoclax,
riTUXimab,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Recommandations fondées sur les données probantes de ContrôleCancerColorectal, le programme ontarien de dépistage du cancer colorectal. Aussi...
Document
Jun 2019
Document
Jun 2019
Blog post
Nausea and vomiting due to cancer treatment are two of the most dreaded side effects of chemotherapy for many patients and their care providers. The...
Jul 2019
Document
Jul 2019
Guidelines and Advice
Status: Current
ID: GL 12-10
Version: 2
Jul 2019

Pages